{"prompt": "['Novartis', 'Confidential', 'Page 26', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'eosinophilic esophagitis). Patients with known parasitic infestation within 6 months prior', 'to Visit 1 are also excluded.', '17. Patients with uncontrolled diabetes having an hemoglobin Alc (HbAlc) test result 8% at', 'the Visit 1 laboratory test.', '18. Patients who have a clinically significant laboratory abnormality at the Visit 1 laboratory', 'test including (but not limited to):', 'Total white blood cell count <2500 cells/L;', 'Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.0 X ULN or', 'total bilirubin >1.3 X ULN;', 'Estimated Glomerular Filtration Rate (eGFR) by the modification of diet in renal', 'disease study (MDRD) equation or Bedside Schwartz equation <55 mL/minute/1.73', 'm2.', '19. Patients who in the judgment of the investigator have a clinically significant condition', 'such as (but not limited to) unstable ischemic heart disease, New York Heart Association', '(NYHA) Class III/IV left ventricular failure, arrhythmia, uncontrolled hypertension,', 'cerebrovascular disease, neurodegenerative diseases, or other neurological disease,', 'uncontrolled hypo- and hyperthyroidism and other autoimmune diseases, hypokalemia,', 'hyperadrenergic state, or ophthalmologic disorder or patients with a medical condition that', 'might compromise patient safety or compliance, interfere with evaluation, or preclude', 'completion of the study.', '20. Patients with a history of myocardial infarction within 12 months of Visit 1.', '21. Patients with serious co-morbidities including, but not limited to, neurodegenerative', 'diseases, rheumatoid arthritis and other autoimmune diseases.', '22. Patients with a history of alcohol or drug abuse within 12 months prior to Visit 1.', '23. Patients with a weight <30 kg at Visit 1.', '24. Patients aged 12 to <18 years below the third percentile for weight by age at Visit 1 (based', 'on local growth charts or the United States Center for Disease Control growth charts', '(Center for Disease Control and Prevention, 2000) if local growth charts are not available).', '25. Patients receiving any other asthma treatment that is not stipulated in Inclusion Criterion', '#4.', '26. Patients receiving any medications in the classes listed in Table 5-3 must be excluded', 'unless they meet the criteria as specified in Table 5-3.', '27. Patients receiving medications in the classes listed in Table 5-1 must be excluded unless', 'the medication has been stabilized for the specified period and the stated conditions have', 'been met.', '28. Patients who started immunotherapy or desensitization for allergies, within 3 months prior', 'to Visit 1, or where the maintenance dose is expected to change during the study.', '29. Patients with a known history of non-compliance to medication or who are unable or', 'unwilling to complete an electronic patient diary or who are unable or unwilling to use the', 'Electronic Peak Expiratory Flow (PEF) with eDiary device or who are unable to', 'demonstrate good eDiary compliance (defined as >70% compliance) during the placebo', 'run-in period.']['Novartis', 'Confidential', 'Page 27', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', '30. Inability to comply with all study requirements and demonstrate good study drug', 'compliance (> 80% compliance) during the placebo run-in period.', \"31. Patients with any medical or psychological condition that, in the investigator's opinion,\", 'renders the patient unable to understand the nature, scope, and possible consequences of', 'the study.', '32. Patients with a history of being unable to swallow tablets.', '33. Patients who have received methotrexate, oral gold, troleandomycin, cyclosporine', 'azathioprine or any experimental anti-inflammatory therapies within 6 months of Visit 101.', '34. Patients with regular use of oral or systemic corticosteroids within 12 months or any intra-', 'articular or short-acting, intramuscular corticosteroid within 1 month or intramuscular,', 'long acting depot corticosteroids within 3 months of Visit 101.', '35. Patients who have a history of or current treatment for hepatic disease including but not', 'limited to acute or chronic hepatitis, cirrhosis or hepatic failure.', '36. Patients with a history of immunodeficiency disease or hepatitis B or hepatitis C.', '37. Patients on >20 mg of simvastatin, > 40 mg of atorvastatin, > 40 mg of pravastatin, or >2', 'mg of pitavastatin. Statin doses less than or equal to these doses as well as other statins', 'will be permitted during the study.', '38. Patients on any statin therapy with a CK level >2 X ULN at Visit 1.', '39. Patients on rifampin, probenecid, ritonavir and valproic acid (i.e. medications blocking', 'several pathways important for the elimination of QAW039 (broad range uridine-', 'diphosphate glucuronosyltransferase (UGT) inhibition and/or inhibition of organic anion', 'transporter 3 (OAT3), organic anion transporter P1B3 (OATP1B3), multi-xenobiotic', 'resistance protein (MXR) and p-glycoprotein (P-gp)).', '40. No person directly associated with the administration of the study is allowed to participate', 'as a study subject.', '41. No family member of the investigational study staff is allowed to participate in this study.', '5', 'Treatment', '5.1', 'Study treatment', '5.1.1', 'Investigational and control drugs', 'The following study drug will be supplied by Novartis to the study sites:', 'Name: QAW039', 'Formulation: tablet', 'Unit dose: 1 strength: 150 mg', \"Please refer to the Investigator's Brochure for composition of the QAW039 tablets.\", 'Name: QAW039 placebo', 'Formulation: tablet', 'Unit dose: matching placebo to QAW039 150 mg']\n\n###\n\n", "completion": "END"}